Nanoparticle-based Drug Delivery Systems for Targeted Epigenetics Cancer Therapy

被引：14
作者：
Chen, Fengqian [1 ]
Shi, Yunzhen [3 ]
Zhang, Jinming [4 ]
Liu, Qi [2 ]
机构：
[1] Texas Tech Univ, Inst Environm & Human Hlth TIEHH, Dept Environm Toxicol, Lubbock, TX 79416 USA
[2] Johns Hopkins Univ, Dept Dermatol, Sch Med, Canc Res Bldg 2,Suite 216,1550 Orleans St, Baltimore, MD 21231 USA
[3] Univ Macau, State Key Lab Qual Res Chinese Med, Inst Chinese Med Sci, Macau, Peoples R China
[4] Chengdu Univ Tradit Chinese Med, Sch Pharm, Chengdu, Peoples R China
来源：
CURRENT DRUG TARGETS | 2020年 / 21卷 / 11期
关键词：
Gene expression; epigenetic regulation/pathway/change; DNA methylation; histone modifications/methylation/acetylation; non-coding RNA; bromodomain; nanoparticle/nanomedicine/nanotechnology; HISTONE DEACETYLASE INHIBITOR; ACUTE MYELOID-LEUKEMIA; SUBEROYLANILIDE HYDROXAMIC ACID; RISK MYELODYSPLASTIC SYNDROME; SOLID LIPID NANOPARTICLES; PH-SENSITIVE MICELLES; LOW-DOSE DECITABINE; CELL LUNG-CANCER; PHASE-II TRIAL; DNA METHYLATION;
D O I：
10.2174/1389450121666200514222900
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
This review summarizes the epigenetic mechanisms of deoxyribonucleic acid (DNA) methylation, histone modifications in cancer and the epigenetic modifications in cancer therapy. Due to their undesired side effects, the use of epigenetic drugs as chemo-drugs in cancer therapies is limited. The drug delivery system opens a door for minimizing these side effects and achieving greater therapeutic benefits. The limitations of current epigenetic therapies in clinical cancer treatment and the advantages of using drug delivery systems for epigenetic agents are also discussed. Combining drug delivery systems with epigenetic therapy is a promising approach to reaching a high therapeutic index and minimizing the side effects.
引用
收藏
页码：1084 / 1098
页数：15
相关论文
共 154 条
[1]  
Adcock Ian M, 2005, COPD, V2, P445
[2]   DNA methylation in breast and colorectal cancers [J].
Agrawal, Anshu ;
Murphy, Richard F. ;
Agrawal, Devendra K. .
MODERN PATHOLOGY, 2007, 20 (07) :711-721
[3]   Two distinct modes for propagation of histone PTMs across the cell cycle [J].
Alabert, Constance ;
Barth, Teresa K. ;
Reveron-Gomez, Nazaret ;
Sidoli, Simone ;
Schmidt, Andreas ;
Jensen, Ole N. ;
Imhof, Axel ;
Groth, Anja .
GENES & DEVELOPMENT, 2015, 29 (06) :585-590
[4]   The molecular hallmarks of epigenetic control [J].
Allis, C. David ;
Jenuwein, Thomas .
NATURE REVIEWS GENETICS, 2016, 17 (08) :487-500
[5]   Valproic acid (VPA) in patients with refractory advanced cancer:: a dose escalating phase I clinical trial [J].
Atmaca, A. ;
Al-Batran, S-E ;
Maurer, A. ;
Neumann, A. ;
Heinzel, T. ;
Hentsch, B. ;
Schwarz, S. E. ;
Hovelmann, S. ;
Goettlicher, M. ;
Knuth, A. ;
Jaeger, E. .
BRITISH JOURNAL OF CANCER, 2007, 97 (02) :177-182
[6]   Histone Modifications and Cancer [J].
Audia, James E. ;
Campbell, Robert M. .
COLD SPRING HARBOR PERSPECTIVES IN BIOLOGY, 2016, 8 (04)
[7]   X-chromosome inactivation: Counting, choice and initiation [J].
Avner, P ;
Heard, E .
NATURE REVIEWS GENETICS, 2001, 2 (01) :59-67
[8]   Epigenetic Determinants of Cancer [J].
Baylin, Stephen B. ;
Jones, Peter A. .
COLD SPRING HARBOR PERSPECTIVES IN BIOLOGY, 2016, 8 (09)
[9]   Reversing epigenetic mechanisms of drug resistance in solid tumors using targeted microRNA delivery [J].
Berman, Melissa ;
Mattheolabakis, George ;
Suresh, Megha ;
Amiji, Mansoor .
EXPERT OPINION ON DRUG DELIVERY, 2016, 13 (07) :987-998
[10]   Concentrations of the DNA methyltransferase inhibitor 5-fluoro-2′-deoxycytidine (FdCyd) and its cytotoxic metabolites in plasma of patients treated with FdCyd and tetrahydrouridine (THU) [J].
Beumer, Jan H. ;
Parise, Robert A. ;
Newman, Edward M. ;
Doroshow, James H. ;
Synold, Timothy W. ;
Lenz, Heinz-Josef ;
Egorin, Merrill J. .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2008, 62 (02) :363-368
12345678910